[go: up one dir, main page]

AR039037A1 - Un sistema de liberacion de una droga vaginal con un ph esencialmente neutro y un metodo para tratar una enfermedad vaginal que comprende dicho sistema - Google Patents

Un sistema de liberacion de una droga vaginal con un ph esencialmente neutro y un metodo para tratar una enfermedad vaginal que comprende dicho sistema

Info

Publication number
AR039037A1
AR039037A1 ARP030100979A ARP030100979A AR039037A1 AR 039037 A1 AR039037 A1 AR 039037A1 AR P030100979 A ARP030100979 A AR P030100979A AR P030100979 A ARP030100979 A AR P030100979A AR 039037 A1 AR039037 A1 AR 039037A1
Authority
AR
Argentina
Prior art keywords
vaginal
phase
essentially neutral
drug
release system
Prior art date
Application number
ARP030100979A
Other languages
English (en)
Inventor
Mitchell I Kirschner
R Saul Levinson
Thomas C Riley
Marc S Hermelin
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22282669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR039037(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of AR039037A1 publication Critical patent/AR039037A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sistema de liberación de una droga vaginal con un pH esencialmente neutro adecuado para la liberación modificada de un material terapéuticamente activo en la cavidad vaginal. El sistema de liberación de la droga vaginal comprende una emulsión con un pH esencialmente neutro que tiene glóbulos que tienen dos fases, una fase interna soluble en agua y una fase externa insoluble en agua o película, en donde la fase interior soluble en agua contiene una droga o drogas terapéuticamente activa(s). Un aspecto novedoso del sistema de liberación de droga vaginal es que la fase interna soluble en agua comprende una fase ácida regulada.
ARP030100979A 2002-03-20 2003-03-20 Un sistema de liberacion de una droga vaginal con un ph esencialmente neutro y un metodo para tratar una enfermedad vaginal que comprende dicho sistema AR039037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/101,014 US6899890B2 (en) 2002-03-20 2002-03-20 Bioadhesive drug delivery system

Publications (1)

Publication Number Publication Date
AR039037A1 true AR039037A1 (es) 2005-02-02

Family

ID=22282669

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100979A AR039037A1 (es) 2002-03-20 2003-03-20 Un sistema de liberacion de una droga vaginal con un ph esencialmente neutro y un metodo para tratar una enfermedad vaginal que comprende dicho sistema

Country Status (17)

Country Link
US (1) US6899890B2 (es)
EP (1) EP1494630A4 (es)
JP (1) JP4462818B2 (es)
KR (2) KR20030076159A (es)
CN (3) CN101045034A (es)
AR (1) AR039037A1 (es)
AU (2) AU2002300175B2 (es)
BR (1) BR0202767A (es)
CA (1) CA2392473C (es)
FR (1) FR2837389A1 (es)
HU (1) HUP0203102A3 (es)
IT (1) ITMI20021660A1 (es)
MX (1) MXPA02006943A (es)
PT (1) PT102854B (es)
RU (1) RU2320322C2 (es)
WO (1) WO2003079981A2 (es)
ZA (1) ZA200407535B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060732B2 (en) * 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
WO2004105662A1 (en) * 2003-05-23 2004-12-09 Program For Appropriate Technology In Health Microbicidal compositions and methods of use
ITTO20030404A1 (it) * 2003-05-30 2004-11-30 Rottapharm S R L Composizione per il ripristino dell'ecosistema vaginale
GB0315671D0 (en) * 2003-07-04 2003-08-13 Chelsea And Westminster Nhs Tr Improvements in or relating to organic compounds
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
US20050095245A1 (en) * 2003-09-19 2005-05-05 Riley Thomas C. Pharmaceutical delivery system
DE602004028284D1 (de) 2003-12-08 2010-09-02 Cpex Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung
US8057433B2 (en) 2004-07-08 2011-11-15 Drugtech Corporation Delivery system
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
BRPI0612968A2 (pt) 2005-04-27 2010-12-14 Shenzhen Phlora Biotechnology Ltd uso do Ácido benzàico e/ou seu sal de sàdio em combinaÇço com sacarÍdeos, composiÇço vaginal e mÉtodo para modular a flora vaginal e a acidez vaginal
WO2006121429A1 (en) * 2005-05-06 2006-11-16 Imaginative Research Associates, Inc. Clindamycin compositions and delivery system therefor
AU2006244260A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
US7786176B2 (en) * 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
WO2007021964A2 (en) 2005-08-11 2007-02-22 Massachusetts Institute Of Technology Intravesical drug delivery device and method
JP2009504667A (ja) * 2005-08-12 2009-02-05 ドラッグテック コーポレイション エストロゲン組成物およびその使用による治療方法
US20070154516A1 (en) * 2006-01-05 2007-07-05 Drugtech Corporation Drug delivery system
CN101374501A (zh) * 2006-01-05 2009-02-25 药物技术公司 组合物及其使用方法
JP2009526064A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション 薬学的調合物
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
US20080003262A1 (en) * 2006-06-30 2008-01-03 Drugtech Corporation Compositions and therapeutic methods of use
US20080085877A1 (en) * 2006-08-10 2008-04-10 Drugtech Corporation Therapeutic methods of using estrogen compositions
US20080268022A1 (en) * 2007-02-23 2008-10-30 Mccabe R Tyler Mehtods for treating and preventing ailments caused by human papillomavirus
US20080287408A1 (en) * 2007-05-14 2008-11-20 Drugtech Corporation Endometriosis treatment
EP1994938A1 (en) * 2007-05-21 2008-11-26 Combinature Biopharm AG New lipoglycodepsipeptide compositions
PL2231254T3 (pl) 2007-12-11 2014-10-31 Massachusetts Inst Technology Implantowane urządzenie do dostarczania leku
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
CA2733468C (en) 2008-08-09 2017-12-05 Massachusetts Institute Of Technology Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
EP2400988B1 (en) * 2009-02-26 2016-04-13 B.R.A.I.N. Biotechnology Research and Information Network AG Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin
CN102481438B (zh) 2009-06-26 2013-09-18 塔里斯生物医药公司 可植入药物递送装置及制造所述装置的方法
US20110008469A1 (en) * 2009-07-09 2011-01-13 Florida Gulf Coast University Antimicrobial composition and methods and apparatus for use thereof
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
RU2479305C2 (ru) * 2010-12-06 2013-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения инфекционных воспалительных заболеваний в гинекологии и способ ее получения
EP2663300B1 (en) 2011-01-10 2023-03-08 TARIS Biomedical LLC Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
US9107816B2 (en) 2011-02-04 2015-08-18 Taris Biomedical Llc Implantable device for controlled dissolution and diffusion of low solubility drug
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US9226908B2 (en) 2011-04-04 2016-01-05 Environ Skin Care (Pty) Ltd Treatment of viral infections
AR086249A1 (es) 2011-05-02 2013-11-27 Aptalis Pharmatech Inc Composiciones de tabletas de disolucion rapida de administracion vaginal
EP2757904B1 (en) * 2011-09-19 2017-01-11 OmniActive Health Technologies Limited An efficient process for the preparation of lycopene containing oleoresin and lycopene crystals for human consumption
US9180094B2 (en) 2011-10-12 2015-11-10 The Texas A&M University System High porosity materials, scaffolds, and method of making
CN104936620B (zh) * 2012-01-19 2019-08-09 约翰霍普金斯大学 增强粘膜渗透的纳米粒子调配物
WO2014018075A1 (en) 2012-07-23 2014-01-30 Crayola, Llc Dissolvable films and methods of using the same
RU2538703C2 (ru) * 2013-03-12 2015-01-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения вагинального кандидоза и способ ее получения
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
WO2014192791A1 (ja) * 2013-05-30 2014-12-04 大正製薬株式会社 坐剤
SMT202000472T1 (it) 2013-08-19 2020-11-10 Taris Biomedical Llc Dispositivi di somministrazione di farmaco multi-unità
WO2015070074A2 (en) 2013-11-08 2015-05-14 The Texas A &M University System Porous microparticles with high loading efficiencies
US20150238549A1 (en) * 2014-02-27 2015-08-27 Mak Wood, Inc. Probiotic dosage units
EP3113824B1 (en) 2014-03-03 2021-04-14 Cook Medical Technologies LLC Mechanical dilator
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法
CA2987520A1 (en) 2015-05-29 2016-12-08 Eve Pharma Ltd. Ph-dependent vaginal compositions and methods of treatment of vaginal disorders
RU2709464C2 (ru) 2015-09-29 2019-12-18 Кимберли-Кларк Ворлдвайд, Инк. Синергическая композиция для сохранения здорового баланса микрофлоры
KR101880179B1 (ko) * 2016-11-03 2018-07-20 한국생명공학연구원 미카펀진(micafungin) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 항바이러스용 약학적 조성물
CN110799198A (zh) * 2016-11-30 2020-02-14 普罗生物瑞士股份公司 用于稳定阴道液的酸度和氧化还原状态的基于合适的生化组合物的泌尿生殖器医疗设备制剂
US12029748B2 (en) 2017-02-28 2024-07-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
CA3123051A1 (en) * 2018-12-19 2020-06-25 Healthy Cow Corporation Ready-to-use probiotic compositions and uses thereof
US11529346B2 (en) * 2020-06-18 2022-12-20 National Medical Supply, LLC Vaginal gel

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988508A (en) * 1973-03-08 1976-10-26 Petrolite Corporation High internal phase ratio emulsion polymers
DE3321043A1 (de) * 1983-06-10 1984-12-13 Bayer Ag, 5090 Leverkusen Antimykotische mittel fuer einmalige gynaekologische behandlung
US4551148A (en) * 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US5266329A (en) * 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US4895452A (en) * 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5298246A (en) * 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
DE69220317T2 (de) * 1991-10-01 1997-10-16 Takeda Chemical Industries Ltd Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
US5189070A (en) * 1992-05-29 1993-02-23 Shell Oil Company Process for preparing low density porous crosslinked polymeric materials
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5470885A (en) * 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
JP2001520999A (ja) * 1997-10-28 2001-11-06 アシビ， エルエルシー 女性の性的機能不全の処置
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system

Also Published As

Publication number Publication date
CN102048689A (zh) 2011-05-11
RU2320322C2 (ru) 2008-03-27
JP4462818B2 (ja) 2010-05-12
HUP0203102A2 (hu) 2004-05-28
ZA200407535B (en) 2006-06-28
AU2002300175A1 (en) 2003-10-09
WO2003079981A3 (en) 2003-11-06
AU2002300175B2 (en) 2004-04-22
WO2003079981A2 (en) 2003-10-02
HUP0203102A3 (en) 2004-06-28
BR0202767A (pt) 2004-05-25
AU2003218233A1 (en) 2003-10-08
US6899890B2 (en) 2005-05-31
CA2392473C (en) 2007-09-18
CN101045034A (zh) 2007-10-03
US20030180366A1 (en) 2003-09-25
JP2003286193A (ja) 2003-10-07
ITMI20021660A1 (it) 2004-01-26
AU2003218233A8 (en) 2003-10-08
KR20030076159A (ko) 2003-09-26
CA2392473A1 (en) 2003-09-20
CN1444926A (zh) 2003-10-01
HU0203102D0 (es) 2002-11-28
RU2004130870A (ru) 2005-06-10
PT102854A (pt) 2003-09-30
MXPA02006943A (es) 2004-12-13
EP1494630A4 (en) 2007-03-14
FR2837389A1 (fr) 2003-09-26
PT102854B (pt) 2004-02-27
KR20080098576A (ko) 2008-11-11
EP1494630A2 (en) 2005-01-12

Similar Documents

Publication Publication Date Title
AR039037A1 (es) Un sistema de liberacion de una droga vaginal con un ph esencialmente neutro y un metodo para tratar una enfermedad vaginal que comprende dicho sistema
JP5435955B2 (ja) 安定な酵素製剤及びその使用方法
US5750141A (en) Administration of vaso-active agent and therapeutic agent
AR044547A1 (es) Sistema de distribucion de drogas
ECSP056076A (es) Sistema de suministro para droga y terapia celular
AR047039A1 (es) Sistema y metodo para administracion transdermica
BR0008058A (pt) Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
AR032293A1 (es) Estuche farmaceutico
Feldman et al. Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
BR0315461A (pt) Sistema terapêutico em forma de pelìcula e processo para a terapia ou para a profilaxia medicinal
BR0210994A (pt) Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e células
Timmons et al. The use of negative‐pressure wound therapy to manage enteroatmospheric fistulae in two patients with large abdominal wounds
ATE206043T1 (de) Örtliche arzneistoffabgabe in tieferen magendarmtraktabschnitten
Marks et al. Pretreatment with allopurinol diminishes pancreatography-induced pancreatitis in a canine model
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
Cavallini Minoxidil versus nitroglycerine: a prospective, double-blind, controlled trial in transcutaneous therapy for organic impotence
FR2872702B3 (fr) Systeme de delivrance
RU2006119263A (ru) Способ лечения больных розацеа
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
RU2321410C1 (ru) Способ лечения воспалительных процессов
CN101401782A (zh) 多拉菌素浇泼剂及其制备方法
RU2630615C1 (ru) Способ консервативного лечения острого геморроя

Legal Events

Date Code Title Description
FB Suspension of granting procedure